KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) R&D In Process (2021 - 2025)

Historic R&D In Process for Bristol Myers Squibb (BMY) over the last 5 years, with Q4 2025 value amounting to $1.4 billion.

  • Bristol Myers Squibb's R&D In Process rose 454333.33% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year decrease of 7216.78%. This contributed to the annual value of $3.7 billion for FY2025, which is 7217.53% down from last year.
  • Latest data reveals that Bristol Myers Squibb reported R&D In Process of $1.4 billion as of Q4 2025, which was up 454333.33% from $633.0 million recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's R&D In Process registered a high of $12.9 billion during Q1 2024, and its lowest value of $6.0 million during Q1 2021.
  • Moreover, its 5-year median value for R&D In Process was $225.0 million (2024), whereas its average is $999.1 million.
  • Its R&D In Process has fluctuated over the past 5 years, first surged by 1716533.33% in 2024, then plummeted by 9854.82% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's R&D In Process (Quarter) stood at $89.0 million in 2021, then crashed by 41.57% to $52.0 million in 2022, then soared by 1053.85% to $600.0 million in 2023, then crashed by 95.0% to $30.0 million in 2024, then skyrocketed by 4543.33% to $1.4 billion in 2025.
  • Its R&D In Process was $1.4 billion in Q4 2025, compared to $633.0 million in Q3 2025 and $1.5 billion in Q2 2025.